Proton pump inhibitors: Risks of long-term use

被引:134
作者
Eusebi, Leonardo Henry [1 ,2 ,3 ]
Rabitti, Stefano [1 ]
Artesiani, Maria Laura [1 ]
Gelli, Dania [1 ]
Montagnani, Marco [1 ]
Zagari, Rocco Maurizio [1 ]
Bazzoli, Franco [1 ]
机构
[1] Univ Bologna, St Orsola Univ Hosp, Dept Med & Surg Sci DIMEC, Gastroenterol & Endoscopy Unit, Bologna, Italy
[2] Royal Free Hampstead NHS Fdn Trust, HPB Dis, London, England
[3] UCL Inst Liver & Digest Hlth, London, England
关键词
complications; long-term risk; proton pump inhibitor; GASTRIC-CANCER; ANTIPLATELET THERAPY; CIRRHOTIC-PATIENTS; GUT MICROBIOME; ACID; ABSORPTION; CALCIUM; METAANALYSIS; OMEPRAZOLE; PANTOPRAZOLE;
D O I
10.1111/jgh.13737
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Proton pump inhibitors are among the most commonly prescribed classes of drugs, and their use is increasing, in particular for long-term treatment, often being over-prescribed and used for inappropriate conditions. In recent years, considerable attention has been directed towards a wide range of adverse effects, and even when a potential underlying biological mechanism is plausible, the clinical evidence of the adverse effect is often weak. Several long-term side effects have been investigated ranging from interaction with other drugs, increased risk of infection, reduced intestinal absorption of vitamins and minerals, and more recently kidney damage and dementia. The most recent literature regarding these adverse effects and their association with long-term proton pump inhibitor treatment is reviewed, and the mechanisms through which these possible complications might develop are discussed.
引用
收藏
页码:1295 / 1302
页数:8
相关论文
共 75 条
  • [1] Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies
    Ahn, Jeong Soo
    Eom, Chun-Sick
    Jeon, Christie Y.
    Park, Sang Min
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (16) : 2560 - 2568
  • [2] Antoniou Tony, 2015, CMAJ Open, V3, pE166, DOI 10.9778/cmajo.20140074
  • [3] Arora P, 2015, J AM SOC NEPHROL, V26, p219A
  • [4] Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function
    Bajaj, Jasmohan S.
    Cox, I. Jane
    Betrapally, Naga S.
    Heuman, Douglas M.
    Schubert, Mitchell L.
    Ratneswaran, Maiyuran
    Hylemon, Phillip B.
    White, Melanie B.
    Daita, Kalyani
    Noble, Nicole A.
    Sikaroodi, Masoumeh
    Williams, Roger
    Crossey, Mary M. E.
    Taylor-Robinson, Simon D.
    Gillevet, Patrick M.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2014, 307 (10): : G951 - G957
  • [5] Altered profile of human gut microbiome is associated with cirrhosis and its complications
    Bajaj, Jasmohan S.
    Heuman, Douglas M.
    Hylemon, Phillip B.
    Sanyal, Arun J.
    White, Melanie B.
    Monteith, Pamela
    Noble, Nicole A.
    Unser, Ariel B.
    Daita, Kalyani
    Fisher, Andmorgan R.
    Sikaroodi, Masoumeh
    Gillevet, Patrick M.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (05) : 940 - 947
  • [6] Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection
    Bavishi, C.
    DuPont, H. L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1269 - 1281
  • [7] BEZWODA W, 1978, J LAB CLIN MED, V92, P108
  • [8] A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use
    Blank, Mei-Ling
    Parkin, Lianne
    Paul, Charlotte
    Herbison, Peter
    [J]. KIDNEY INTERNATIONAL, 2014, 86 (04) : 837 - 844
  • [9] Incidence of Campylobacter and Salmonella Infections Following First Prescription for PPI: A Cohort Study Using Routine Data
    Brophy, Sinead
    Jones, Kerina H.
    Rahman, Muhammad A.
    Zhou, Shang-Ming
    John, Ann
    Atkinson, Mark D.
    Francis, Nick
    Lyons, Ronan A.
    Dunstan, Frank
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (07) : 1094 - 1100
  • [10] Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease
    Brunner, G.
    Athmann, C.
    Schneider, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (01) : 37 - 47